|
DEAFNESS, AUTOSOMAL DOMINANT 66
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
A Novel Locus Harbouring a Functional CD164 Nonsense Mutation Identified in a Large Danish Family with Nonsyndromic Hearing Impairment.
|
26197441 |
2015 |
|
DEAFNESS, AUTOSOMAL DOMINANT 66
|
0.600 |
Biomarker
|
disease |
CLINGEN |
A Novel Locus Harbouring a Functional CD164 Nonsense Mutation Identified in a Large Danish Family with Nonsyndromic Hearing Impairment.
|
26197441 |
2015 |
|
DEAFNESS, AUTOSOMAL DOMINANT 66
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Nonsyndromic Deafness
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
In this study we used SNP-based linkage analysis and follow up microsatellite markers to identify a novel locus (DFNA66) on chromosome 6q15-21 (LOD 5.1) in a large Danish family with dominantly inherited NSHI.
|
26197441 |
2015 |
|
Nonsyndromic Deafness
|
0.310 |
Biomarker
|
disease |
CLINGEN |
In this study we used SNP-based linkage analysis and follow up microsatellite markers to identify a novel locus (DFNA66) on chromosome 6q15-21 (LOD 5.1) in a large Danish family with dominantly inherited NSHI.
|
26197441 |
2015 |
|
Spontaneous abortion
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Abortion, Tubal
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Early Pregnancy Loss
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Miscarriage
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Blood basophil count (lab test)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
Sensorineural Hearing Loss (disorder)
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Variable expressivity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The immunohistochemistry (IHC) was performed to evaluate the associations between the expression level of CD164 and clinical-pathological features of patients, and IHC was used to analyze the relationship between CD164 and CXCR4 in tumor tissues.
|
30022623 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
To further characterize CD164 as a potential biomarker for malignant CD4<sup>+</sup> T cells, CD164<sup>+</sup> and CD164<sup>-</sup>CD4<sup>+</sup> T cells isolated from patients with high-circulating tumor burden, B2 stage, and medium/low tumor burden, B1-B0 stage, were assessed for the expression of genes reported to differentiate SS from normal controls, and associated with malignancy and poor prognosis.
|
27766406 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
CD164 is regarded to be a potential promotor of tumor growth.
|
28259931 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In conclusion, we have provided evidence that CD164 promotes the growth of lung tumor-initiating cells with stem cell properties and induces tumor growth and drug resistance through Akt/mTOR signaling.
|
28903328 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Our results suggest that CD164 can serve as a marker for diagnosis and for monitoring progression of cutaneous T-cell lymphoma (CTCL)/SS and that FCRL3 expression correlates with a high circulating tumor burden.
|
23792457 |
2014 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The clinicopathological correlation analysis showed that the upregulation of CD164 protein was significantly associated with tumor grade and metastasis.
|
24094005 |
2013 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
CD164 regulates proliferation, progression, and invasion of human glioblastoma cells.
|
31007847 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
High level of CD164 was related to the distant metastasis and vascular invasion of bladder cancer patients.
|
30022623 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
High level of CD164 was related to the distant metastasis and vascular invasion of bladder cancer patients.
|
30022623 |
2018 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Emerging evidence indicates that elevated CD164 expression is associated with aggressive metastasis, advanced stages, and shorter overall survival in lung cancer.
|
28903328 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
The clinicopathological correlation analysis showed that the upregulation of CD164 protein was significantly associated with tumor grade and metastasis.
|
24094005 |
2013 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Given that IMP3 is an mRNA-binding protein, we determined that it binds several key mRNAs that could contribute to migration and invasion, including CD164 (endolyn) and MMP9.
|
22266872 |
2012 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
LHGDN |
Our findings suggest that CD164 may participate in the localization of prostate cancer cells to the marrow and is further evidence that tumor metastasis and hematopoietic stem cell trafficking may involve similar processes.
|
16859559 |
2006 |